{"id":"AIBD-0930","title":"SHTG finds that the Dxcover blood test, read by machine learning, told apart patients with and without brain cancer in a hospital cohort","summary":"SHTG found that the Dxcover test distinguished patients with and without brain cancer in a cohort of 385, with a negative predictive value of 95%. Its use in primary care is untested.","date_observed":"2021-10-01","date_basis":"source publication","date_precision":"month","benefit_status":"mixed","source_collection":null,"source_entry":null,"account":"Dxcover Ltd is developing a blood test that reads the infrared spectrum of a serum sample and uses machine learning to spot the pattern of brain cancer. At the developers' request, the Scottish Health Technologies Group (SHTG) assessed the evidence and published its overview in October 2021. The published study tested 385 people at a single center in Edinburgh. They were 321 patients referred from primary care for CT scans and 64 patients with known brain tumors. Sensitivity was 81% and specificity 80%, for a negative predictive value of 95% and a positive predictive value of 45%. SHTG notes that the cohort was enriched with known tumors and did not match the primary care patients for whom the test is meant. The referred group held only three tumors. In an exploratory model, the test was likely to be cost-effective at £100 if 1% of tested patients had brain cancer. Directors and an employee of ClinSpec Diagnostics, the spinout company whose staff developed the test, co-wrote the study. SHTG states that firm conclusions cannot be drawn without evaluation in general practice.","category":"aggregate result","unexpected":false,"purpose":"Dxcover Ltd built the Dxcover brain cancer liquid biopsy test to help general practitioners decide which patients with vague symptoms to send urgently for brain imaging.","system":"Dxcover brain cancer liquid biopsy test","model_version":null,"developer":"Dxcover Ltd","deployer":"Brain tumor early diagnosis study in NHS Lothian at the Western General Hospital, Edinburgh (patients referred for direct-access CT and patients with new brain tumors)","location":"Edinburgh, Scotland, United Kingdom","domain":"Healthcare (cancer diagnostics)","segment":null,"benefit_type":"Improved Task Accuracy","work_activities":["4.A.1.b.1"],"taxonomy_note":null,"registry_ids":{},"ratings":[{"group":"personal","depth":null,"reason":"Samples were tested blind to imaging, so no patient's referral depended on the result."}],"ai_role":{"status":"unassessed","statement":"SHTG states that the test uses machine learning to find patterns in serum spectra and diagnostic algorithms to predict which patients have the disease. The study measured the whole test against CT imaging and did not compare referral decisions with and without it."},"evidence":[{"kind":"assessment report","citation":"Scottish Health Technologies Group, Healthcare Improvement Scotland. Dxcover™ brain cancer liquid biopsy test for early brain cancer detection in primary care. Innovative Medical Technology Overview IMTO 03-21, October 2021. Executive summary.","title":"Dxcover™ brain cancer liquid biopsy test for early brain cancer detection in primary care","url":"https://shtg.scot/media/2110/dxcover-brain-cancer-liquid-biopsy-test-for-early-brain-cancer-detection-in-primary-care-imto-v10.pdf","date":null,"written_by":"independent","quote":"In a published diagnostic accuracy cohort study (n=385) undertaken in secondary care that included 64 patients with known brain tumours, the DxcoverTM test was able to distinguish between patients with and without brain cancer."},{"kind":"peer-reviewed study","citation":"Brennan PM, Butler HJ, Christie L, et al. Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy. Brain Communications 2021, 3(2):fcab056. doi:10.1093/braincomms/fcab056. Four authors were directors and one an employee of ClinSpec Diagnostics, the spinout company behind the test.","title":"Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8111062/","date":"2021-03-30","written_by":"makers","quote":"Our test predicted the presence of glioblastoma, the most common and aggressive brain tumour, with 91% sensitivity, and all brain tumours with 81% sensitivity, and 80% specificity."}],"replication":{"produced_by":["Serum samples were analyzed by infrared spectroscopy and a machine-learning algorithm, blind to the imaging results.","The cohort combined patients referred for direct-access CT with patients already diagnosed with brain tumors."],"must_hold":["Accuracy is confirmed in the primary care population for whom the test is meant.","About 1% or more of tested patients have brain cancer, the level at which the test was likely to be cost-effective at £100 in the exploratory model."],"echoes":[]},"paired_incident":null,"headline":"*Dxcover* blood test separated patients with and without brain cancer","metric":"a negative predictive value of 95%","comparator":null,"later":null,"value":null,"developer_country":"United Kingdom","deployer_country":"United Kingdom","unrated_because":"The test was run blind on samples from an enriched hospital cohort, and SHTG judged that its benefit in primary care is unproven.","brief_notes":null,"brief":null,"revisions":[{"date":"2026-10-31","change":"Added the record from the finding of the Scottish Health Technologies Group.","source":"https://shtg.scot/media/2110/dxcover-brain-cancer-liquid-biopsy-test-for-early-brain-cancer-detection-in-primary-care-imto-v10.pdf","editor":"AIBD"}],"confidence":"found","shade":"high","claim_status":"Found by an assessment body","claim_basis":"Sources: one independent assessment report and the makers' peer-reviewed study. The cited evidence includes no independent study or report.","case_jurisdictions":["United Kingdom"],"profile":{"case_id":"AIBD-0930","catalog_version":"1.0.0","source_fingerprint":"080906f441d7f103dcb6c34e0f7b3c5f1954201e50650e10e1a6d385167c304c","collection_refs":[{"collection_id":"aibd","version":"2026-10-31"},{"collection_id":"querist","version":"2026-10-25"}],"source_ids":["AIBD-0930-source-0001","AIBD-0930-source-0002"],"families":{"strategic assessments":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"Editorial assignment.","review_state":"not_assessed","coverage":"partial","record_ids":[]},"evaluations":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"Editorial assignment.","review_state":"not_assessed","coverage":"partial","record_ids":[]},"monetary observations":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"Editorial assignment.","review_state":"not_assessed","coverage":"partial","record_ids":[]},"institutional decisions":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"Editorial assignment.","review_state":"not_assessed","coverage":"partial","record_ids":[]}},"fields":{"actors[]":{"state":"value_present","value":{"kind":"record_fields","fields":{"developer":"Dxcover Ltd","deployer":"Brain tumor early diagnosis study in NHS Lothian at the Western General Hospital, Edinburgh (patients referred for direct-access CT and patients with new brain tumors)"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["developer","deployer"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"actors[].ownership_control":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"ai_contribution":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"ai_relationship":{"state":"value_present","value":{"kind":"record_fields","fields":{"category":"aggregate result","ai_role":{"status":"unassessed","statement":"SHTG states that the test uses machine learning to find patterns in serum spectra and diagnostic algorithms to predict which patients have the disease. The study measured the whole test against CT imaging and did not compare referral decisions with and without it."}}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ai_role","category"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"assessments[].alternatives":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].assessor_date":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].depth":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].display_confidence":{"state":"value_present","value":{"kind":"structured","data":{"confidence":"high","evidence_word":"found","claim_status":"Found by an assessment body","basis":"Sources: one independent assessment report and the makers' peer-reviewed study. The cited evidence includes no independent study or report.","interpretation":"Existing display rule preserved; the richer outcome-specific confidence question still needs review."}},"provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"assessments[].rationale":{"state":"value_present","value":{"kind":"record_fields","fields":{"ratings":[{"group":"personal","reason":"Samples were tested blind to imaging, so no patient's referral depended on the result."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ratings"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"assessments[].rubric_version":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].status_basis":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].target":{"state":"value_present","value":{"kind":"record_fields","fields":{"ratings":[{"group":"personal","reason":"Samples were tested blind to imaging, so no patient's referral depended on the result."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ratings"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"availability":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"brief":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"case_kind":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"case_links[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"claims[].evidence_links":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"claims[].evidence_strength":{"state":"value_present","value":{"kind":"structured","data":{"answer":"Found by an assessment body. Sources: one independent assessment report and the makers' peer-reviewed study. The cited evidence includes no independent study or report.","evidence_word":"found","claim_status":"Found by an assessment body"}},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0930-source-0001","AIBD-0930-source-0002"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Found by an assessment body. Sources: one independent assessment report and the makers' peer-reviewed study. The cited evidence includes no independent study or report.","inferred":false}},"claims[].missingness":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"claims[].proposition":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"cross_border_flows[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"decisions[].action_outcome":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"decisions[].grounds":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"decisions[].institution_task":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"decisions[].success_criterion":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"deployment_stage":{"state":"value_present","value":{"kind":"structured","data":{"classification":"laboratory test","answer":"The system was tested in a laboratory. Stored serum samples were tested blind to imaging, and SHTG reports that the test was in late-stage technical development.","scope":"The period and activity described in the case."}},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["account","evidence"],"source_refs":["AIBD-0930-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"The system was tested in a laboratory. Stored serum samples were tested blind to imaging, and SHTG reports that the test was in late-stage technical development.","inferred":false}},"economics[].amount":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].costs[]":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].counterfactual":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].currency_price_basis":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].gross_net":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].measure_type":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].period_unit":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].realization":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].recipient_payer":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].return_payback":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].valuation_method":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"evaluations[].ai_uplift":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].comparator":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].design":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].effect":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].exposure":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].id":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].measurement_method":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].metric":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].reproduction_materials":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].setting_sample":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"evaluations[].uncertainty_limitations":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"evaluations"},"external_references[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"follow_up[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"human_oversight":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"id":{"state":"value_present","value":{"kind":"record_fields","fields":{"id":"AIBD-0930"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["id"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"infrastructure_dependencies[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].beneficiaries":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].beneficiary_count":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].benefit_type":{"state":"value_present","value":{"kind":"record_fields","fields":{"benefit_type":"Improved Task Accuracy"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["benefit_type"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"outcomes[].claim":{"state":"value_present","value":{"kind":"record_fields","fields":{"account":"Dxcover Ltd is developing a blood test that reads the infrared spectrum of a serum sample and uses machine learning to spot the pattern of brain cancer. At the developers' request, the Scottish Health Technologies Group (SHTG) assessed the evidence and published its overview in October 2021. The published study tested 385 people at a single center in Edinburgh. They were 321 patients referred from primary care for CT scans and 64 patients with known brain tumors. Sensitivity was 81% and specificity 80%, for a negative predictive value of 95% and a positive predictive value of 45%. SHTG notes that the cohort was enriched with known tumors and did not match the primary care patients for whom the test is meant. The referred group held only three tumors. In an exploratory model, the test was likely to be cost-effective at £100 if 1% of tested patients had brain cancer. Directors and an employee of ClinSpec Diagnostics, the spinout company whose staff developed the test, co-wrote the study. SHTG states that firm conclusions cannot be drawn without evaluation in general practice.","benefit_type":"Improved Task Accuracy"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["account","benefit_type"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"outcomes[].distribution":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].duration":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].id":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].stakeholder_group":{"state":"value_present","value":{"kind":"record_fields","fields":{"ratings":[{"group":"personal","reason":"Samples were tested blind to imaging, so no patient's referral depended on the result."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ratings"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"outcomes[].status":{"state":"value_present","value":{"kind":"record_fields","fields":{"benefit_status":"mixed"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["benefit_status"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"outcomes[].tradeoffs":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].unexpected":{"state":"value_present","value":{"kind":"record_fields","fields":{"unexpected":false,"purpose":"Dxcover Ltd built the Dxcover brain cancer liquid biopsy test to help general practitioners decide which patients with vague symptoms to send urgently for brain imaging."}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["unexpected","purpose"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"places[]":{"state":"value_present","value":{"kind":"record_fields","fields":{"location":"Edinburgh, Scotland, United Kingdom","developer_country":"United Kingdom","deployer_country":"United Kingdom"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["location","developer_country","deployer_country"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"purpose":{"state":"value_present","value":{"kind":"record_fields","fields":{"purpose":"Dxcover Ltd built the Dxcover brain cancer liquid biopsy test to help general practitioners decide which patients with vague symptoms to send urgently for brain imaging."}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["purpose"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"record_dates":{"state":"value_present","value":{"kind":"record_fields","fields":{"date_observed":"2021-10-01","date_basis":"source publication","date_precision":"month","revisions":[{"date":"2026-10-31","change":"Added the record from the finding of the Scottish Health Technologies Group.","source":"https://shtg.scot/media/2110/dxcover-brain-cancer-liquid-biopsy-test-for-early-brain-cancer-detection-in-primary-care-imto-v10.pdf","editor":"AIBD"}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["date_observed","date_basis","date_precision","revisions"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"replication.attempts[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"replication.conditions":{"state":"value_present","value":{"kind":"record_fields","fields":{"replication":{"produced_by":["Serum samples were analyzed by infrared spectroscopy and a machine-learning algorithm, blind to the imaging results.","The cohort combined patients referred for direct-access CT with patients already diagnosed with brain tumors."],"must_hold":["Accuracy is confirmed in the primary care population for whom the test is meant.","About 1% or more of tested patients have brain cancer, the level at which the test was likely to be cost-effective at £100 in the exploratory model."],"echoes":[]}}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["replication"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"revision_history[]":{"state":"value_present","value":{"kind":"record_fields","fields":{"revisions":[{"date":"2026-10-31","change":"Added the record from the finding of the Scottish Health Technologies Group.","source":"https://shtg.scot/media/2110/dxcover-brain-cancer-liquid-biopsy-test-for-early-brain-cancer-detection-in-primary-care-imto-v10.pdf","editor":"AIBD"}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["revisions"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sector":{"state":"value_present","value":{"kind":"record_fields","fields":{"domain":"Healthcare (cancer diagnostics)"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["domain"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sources[].access_version":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"sources[].citation_locator":{"state":"value_present","value":{"kind":"record_fields","fields":{"evidence":[{"kind":"assessment report","citation":"Scottish Health Technologies Group, Healthcare Improvement Scotland. Dxcover™ brain cancer liquid biopsy test for early brain cancer detection in primary care. Innovative Medical Technology Overview IMTO 03-21, October 2021. Executive summary.","title":"Dxcover™ brain cancer liquid biopsy test for early brain cancer detection in primary care","url":"https://shtg.scot/media/2110/dxcover-brain-cancer-liquid-biopsy-test-for-early-brain-cancer-detection-in-primary-care-imto-v10.pdf","written_by":"independent","quote":"In a published diagnostic accuracy cohort study (n=385) undertaken in secondary care that included 64 patients with known brain tumours, the DxcoverTM test was able to distinguish between patients with and without brain cancer."},{"kind":"peer-reviewed study","citation":"Brennan PM, Butler HJ, Christie L, et al. Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy. Brain Communications 2021, 3(2):fcab056. doi:10.1093/braincomms/fcab056. Four authors were directors and one an employee of ClinSpec Diagnostics, the spinout company behind the test.","title":"Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8111062/","date":"2021-03-30","written_by":"makers","quote":"Our test predicted the presence of glioblastoma, the most common and aggressive brain tumour, with 91% sensitivity, and all brain tumours with 81% sensitivity, and 80% specificity."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sources[].id":{"state":"value_present","value":{"kind":"identifiers","identifiers":["AIBD-0930-source-0001","AIBD-0930-source-0002"],"role":"Existing evidence items, in their original order"},"provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"review_state":"record_mapped","coverage":"complete"},"sources[].language":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"sources[].relationship":{"state":"value_present","value":{"kind":"record_fields","fields":{"evidence":[{"kind":"assessment report","citation":"Scottish Health Technologies Group, Healthcare Improvement Scotland. Dxcover™ brain cancer liquid biopsy test for early brain cancer detection in primary care. Innovative Medical Technology Overview IMTO 03-21, October 2021. Executive summary.","title":"Dxcover™ brain cancer liquid biopsy test for early brain cancer detection in primary care","url":"https://shtg.scot/media/2110/dxcover-brain-cancer-liquid-biopsy-test-for-early-brain-cancer-detection-in-primary-care-imto-v10.pdf","written_by":"independent","quote":"In a published diagnostic accuracy cohort study (n=385) undertaken in secondary care that included 64 patients with known brain tumours, the DxcoverTM test was able to distinguish between patients with and without brain cancer."},{"kind":"peer-reviewed study","citation":"Brennan PM, Butler HJ, Christie L, et al. Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy. Brain Communications 2021, 3(2):fcab056. doi:10.1093/braincomms/fcab056. Four authors were directors and one an employee of ClinSpec Diagnostics, the spinout company behind the test.","title":"Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8111062/","date":"2021-03-30","written_by":"makers","quote":"Our test predicted the presence of glioblastoma, the most common and aggressive brain tumour, with 91% sensitivity, and all brain tumours with 81% sensitivity, and 80% specificity."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sources[].upstream_sources":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"strategic_assessments[]":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"strategic assessments"},"summary":{"state":"value_present","value":{"kind":"record_fields","fields":{"summary":"SHTG found that the Dxcover test distinguished patients with and without brain cancer in a cohort of 385, with a negative predictive value of 95%. Its use in primary care is untested.","account":"Dxcover Ltd is developing a blood test that reads the infrared spectrum of a serum sample and uses machine learning to spot the pattern of brain cancer. At the developers' request, the Scottish Health Technologies Group (SHTG) assessed the evidence and published its overview in October 2021. The published study tested 385 people at a single center in Edinburgh. They were 321 patients referred from primary care for CT scans and 64 patients with known brain tumors. Sensitivity was 81% and specificity 80%, for a negative predictive value of 95% and a positive predictive value of 45%. SHTG notes that the cohort was enriched with known tumors and did not match the primary care patients for whom the test is meant. The referred group held only three tumors. In an exploratory model, the test was likely to be cost-effective at £100 if 1% of tested patients had brain cancer. Directors and an employee of ClinSpec Diagnostics, the spinout company whose staff developed the test, co-wrote the study. SHTG states that firm conclusions cannot be drawn without evaluation in general practice."}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["summary","account"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"systems[].autonomy_permissions":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].component_role":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].deployment_configuration":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].inputs_outputs":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].model_name":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].model_version":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].product_name":{"state":"value_present","value":{"kind":"record_fields","fields":{"system":"Dxcover brain cancer liquid biopsy test"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["system"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"systems[].provider":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"taxonomy_crosswalks[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"title":{"state":"value_present","value":{"kind":"record_fields","fields":{"title":"SHTG finds that the Dxcover blood test, read by machine learning, told apart patients with and without brain cancer in a hospital cohort","headline":"*Dxcover* blood test separated patients with and without brain cancer"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["title","headline"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"version":{"state":"value_present","value":{"kind":"identifiers","identifiers":["1063fee9589dbe0c2b17914958585901d08c1361848cd4214d54d66075b3ca46"],"role":"SHA-256 of the complete public record and its assessments"},"provenance":{"kind":"curatorial","basis":"SHA-256 of the public record, its assessments, and its displayed answers and notes, excluding its own identifier and the derived coverage summary.","record_fields":[],"source_refs":[]},"review_state":"record_mapped","coverage":"complete"},"workflow":{"state":"value_present","value":{"kind":"record_fields","fields":{"account":"Dxcover Ltd is developing a blood test that reads the infrared spectrum of a serum sample and uses machine learning to spot the pattern of brain cancer. At the developers' request, the Scottish Health Technologies Group (SHTG) assessed the evidence and published its overview in October 2021. The published study tested 385 people at a single center in Edinburgh. They were 321 patients referred from primary care for CT scans and 64 patients with known brain tumors. Sensitivity was 81% and specificity 80%, for a negative predictive value of 95% and a positive predictive value of 45%. SHTG notes that the cohort was enriched with known tumors and did not match the primary care patients for whom the test is meant. The referred group held only three tumors. In an exploratory model, the test was likely to be cost-effective at £100 if 1% of tested patients had brain cancer. Directors and an employee of ClinSpec Diagnostics, the spinout company whose staff developed the test, co-wrote the study. SHTG states that firm conclusions cannot be drawn without evaluation in general practice.","replication":{"produced_by":["Serum samples were analyzed by infrared spectroscopy and a machine-learning algorithm, blind to the imaging results.","The cohort combined patients referred for direct-access CT with patients already diagnosed with brain tumors."],"must_hold":["Accuracy is confirmed in the primary care population for whom the test is meant.","About 1% or more of tested patients have brain cancer, the level at which the test was likely to be cost-effective at £100 in the exploratory model."],"echoes":[]}}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["account","replication"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"}},"summary":{"total":91,"addressed":91,"known":27,"reviewed":2,"reviewed_complete":2,"reviewed_partial":0,"record_mapped":25,"review_not_assessed":64,"not_assessed":0,"complete":false,"by_state":{"value_present":27,"not_reported":0,"unresolved":64,"not_assessed":0,"not_applicable":0,"withheld":0,"source_unavailable":0}}},"presentation_version":"e74d742d362b0009d350eccf87f387039a4a6550dafb7427ac9cae2a1f9812cc"}